Patents by Inventor Ben Hitchinson

Ben Hitchinson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • POTENCY ASSAY
    Publication number: 20230221303
    Abstract: A method for assessing the potency of MSCs to produce anti-inflammatory cytokines in response to a pro-inflammatory stimulus. The method comprises stimulating the MSCs with one or more proinflammatory cytokines, such as TNF-?, for a duration of time and then identifying and quantifying the production of anti-inflammatory cytokines. MSCs that produce potent levels of anti-inflammatory cytokines in response to TNF-? can be used in treatments for aging-related conditions, including aging frailty and Alzheimer's disease, and can also be used to treat corona virus infections. The method shows that TNF-? induced MSCs robustly secrete several anti-inflammatory cytokines, including IL-1 receptor antagonist (IL-1RA), IL-10, and granulocyte colony stimulating factor (G-CSF).
    Type: Application
    Filed: April 20, 2021
    Publication date: July 13, 2023
    Applicant: Longeveron Inc.
    Inventors: Anthony A. Oliva, Ben Hitchinson
  • Peptide inhibition of CCR3-mediated diseases or conditions
    Patent number: 11167012
    Abstract: A C—C chemokine receptor 3 (CCR3) peptide analog that exhibits biased antagonism by binding to and inhibiting ligand-mediated signaling and chemotaxis while promoting the internalization and degradation of CCR3 is provided as is a method of using the peptide analog to treat, prevent, or ameliorate one or more symptoms of an eosinophil- or CCR3-mediated disease or condition.
    Type: Grant
    Filed: July 29, 2019
    Date of Patent: November 9, 2021
    Assignees: The Board of Trustees of the University of Illinois, The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Steven Jules Ackerman, Fan Gao Laffey, Ben Hitchinson, Boris Garnier, Vadim Gaponenko, Nadya Tarasova, Hazem Abdelkarim
  • PEPTIDE INHIBITION OF CCR3-MEDIATED DISEASES OR CONDITIONS
    Publication number: 20190374608
    Abstract: A C—C chemokine receptor 3 (CCR3) peptide analog that exhibits biased antagonism by binding to and inhibiting ligand-mediated signaling and chemotaxis while promoting the internalization and degradation of CCR3 is provided as is a method of using the peptide analog to treat, prevent, or ameliorate one or more symptoms of an eosinophil- or CCR3-mediated disease or condition.
    Type: Application
    Filed: July 29, 2019
    Publication date: December 12, 2019
    Inventors: Steven Jules Ackerman, Fan Gao Laffey, Ben Hitchinson, Boris Garnier, Vadim Gaponenko, Nadya Tarasova, Hazem Abdelkarim
  • Peptide inhibition of CCR3-mediated diseases or conditions
    Patent number: 10363286
    Abstract: A C—C chemokine receptor 3 (CCR3) peptide analog that exhibits biased antagonism by binding to and inhibiting ligand-mediated signaling and chemotaxis while promoting the internalization and degradation of CCR3 is provided as is a method of using the peptide analog to treat, prevent, or ameliorate one or more symptoms of an eosinophil- or CCR3-mediated disease or condition.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: July 30, 2019
    Assignees: The Board of Trustees of the University of Illinois, The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Steven Jules Ackerman, Fan Gao Laffey, Ben Hitchinson, Boris Garnier, Vadim Gaponenko, Nadya Tarasova, Hazem Abdelkarim
  • PEPTIDE INHIBITION OF CCR3-MEDIATED DISEASES OR CONDITIONS
    Publication number: 20170304401
    Abstract: A C—C chemokine receptor 3 (CCR3) peptide analog that exhibits biased antagonism by binding to and inhibiting ligand-mediated signaling and chemotaxis while promoting the internalization and degradation of CCR3 is provided as is a method of using the peptide analog to treat, prevent, or ameliorate one or more symptoms of an eosinophil- or CCR3-mediated disease or condition.
    Type: Application
    Filed: June 30, 2017
    Publication date: October 26, 2017
    Inventors: Steven Jules Ackerman, Fan Gao Laffey, Ben Hitchinson, Boris Garnier, Vadim Gaponenko, Nadya Tarasova, Hazem Abdelkarim